20 Mar Oncology Based In-Vivo CRO Market 2025-2033: Global Industry Analysis, Share, Size, Growth and Forecast
MARKET OVERVIEW:
The global oncology-based in-vivo contract research organization (CRO) market is poised for significant growth, with its size reaching USD 1.3 billion in 2024 and expected to surge to USD 2.4 billion by 2033. This growth is fueled by rising cancer prevalence, continuous technological advancements, and an increasing demand for personalized treatments. As healthcare focuses more on tailored therapies and regulatory compliance, the market is witnessing strong momentum, driven by innovations in research methodologies and clinical trial models.
STUDY ASSUMPTION YEARS:
- BASE YEAR: 2024
- HISTORICAL YEAR: 2019-2024
- FORECAST YEAR: 2025-2033
ONCOLOGY BASED IN-VIVO CRO MARKET KEY TAKEAWAYS:
- The market size in 2024 is USD 1.3 billion, expected to grow at a CAGR of 6.55%, reaching USD 2.4 billion by 2033.
- Cancer prevalence worldwide is rising, leading to increased demand for in-vivo CRO services.
- Technological advancements, especially in imaging and diagnostics, are expanding the capabilities of CROs in oncology.
- Personalized medicine continues to drive demand for tailored treatment approaches.
- North America leads the global market, with strong healthcare infrastructure and research investment.
- Virtual clinical trials and telehealth adoption are reshaping oncology research methodologies.
- Governments’ investments in oncology research are significantly boosting the CRO market.
MARKET GROWTH FACTORS:
Technological Developments in Diagnostic Imaging:
Technological advances in in vivo oncology research directly affect the development of the CRO market. Innovations like PET-CT, MRI, and advanced tumor visualization in either diagnostics or treatment of cancer have made the whole process increasingly accurate. More and more advanced scanners such as Biograph Trinion from Siemens Healthineers mean correspondingly better spatial resolution and faster scans, tracking the disease course and treatment response, thus making in vivo CRO services more relevant to modern oncological research.
Rising Cancer Incidence and Increasing Investments in Research:
An increasing global burden of cancer is one of the primary market drivers. With almost 20 million new cancer cases being added every year and given predictions that this number will rise to 35 million by the year 2050, the demand for new anti-cancer treatment research has never been higher. Government and private funding toward cancer research has surged, thereby increasing the demand for CROs that are specialized. The very complicated nature of cancer would demand highly advanced clinical trials, affording plenty of opportunities to the CROs involved in oncology research.
Transition to Personalized Medicine:
Personalized medicine is shaking the foundations of oncology by giving rise to prepared treatment regimens that increase efficacy and lower adverse effects. An increase in demand for in vivo CROs providing specialized oncology research services is expected with the increasing prevalence of personalized approaches that require a solid understanding of genetic and molecular data, with CROs increasingly providing services in line with those individualized treatment regimens. This transition is predicted to sustain the market growth of oncology-based in vivo CROs for years to come.
Request Sample For PDF Report: https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample
Market Segmentation:
Breakup by Indication:
- Blood Cancer
- Solid Tumors
- Others
Breakup by Model:
- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)
- Others
Breakup by Application:
- Hospitals
- Rehabilitation Centers
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
REGIONAL INSIGHTS:
North America leads the oncology-based in-vivo CRO market, driven by a strong healthcare infrastructure, increasing cancer incidence, and significant investments in cancer research. The region’s demand for specialized cancer treatments and clinical trials continues to grow, supported by cutting-edge technological advancements and regulatory frameworks designed to promote innovative healthcare solutions.
RECENT DEVELOPMENTS & NEWS:
In recent developments, the oncology-based in-vivo CRO market has seen an increase in the adoption of virtual clinical trials and telehealth. This shift aims to provide safer, more accessible clinical trials for cancer patients, ensuring that treatments remain effective while minimizing patient risks. Additionally, advancements in personalized medicine are pushing the boundaries of cancer research, requiring more precise and individualized clinical models.
Key Players:
- Champions Oncology Inc.
- Charles River Laboratories International Inc.
- Crown Bioscience Inc.
- Eurofins Scientific
- Evotec SE
- ICON Plc
- Labcorp Drug Development (Laboratory Corporation of America Holdings)
- Living Tumor Laboratory
- Taconic Biosciences Inc.
- The Jackson Laboratory
- WuXi AppTec
- Xentech
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Sin comentarios